All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
JUMP trial: How do patients with MF and lower grade fibrosis benefit from ruxolitinib?
Featured:
Haifa Kathrin Al-AliDuring the EHA2021 Virtual Congress, the MPN Hub spoke with Haifa Kathrin Al-Ali, University Hospital Halle (Saale), Halle, DE. We asked, How do patients with myelofibrosis (MF) and lower grade fibrosis benefit from ruxolitinib?
JUMP trial: How do patients with MF and lower grade fibrosis benefit from ruxolitinib?
In this video, Al-Ali discusses insights from the JUMP trial, evaluating the impact of ruxolitinib on low-grade bone marrow fibrosis. She touches upon the degree of fibrosis, time to diagnosis, survival and long-term outcomes, prognostic factors, and response rates.